Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AZN: AstraZeneca PLC -- Ignore unavailable to you. Want to Upgrade?

To: EdR who wrote (16)	7/27/2002 12:58:00 PM
From: Ausdauer	Read Replies (1) \| Respond to of 35

Ed, I haven't gone through the numbers in great detail. They seem to be doing a good job promoting Nexium while reverse detailing Prilosec. Good marketing can require a substantial monetary invetment. The growth rate is somewhat concerning. I read a recent article in an investment magazine that stated all the "low hanging fruit" in the health care arena has already been plucked. That is to say the common illnesses--hypertension, hyperlipidemia, arthritis, impotence, depression, anxiety, infectious diseases...--have all been addressed. What remains is less common illnesses with a much smaller overall market. One area that is huge and unserved is oral anticoagulation for diseases like atrial fib, deep venous thrombosis, pulmonary embolism, prosthetic heart valves, etc... These are, in general, diseases of the elderly. This market is not only large, but growing. AZN may have a chance for substantial growth here. eurekalert.org Aus